Physician profile
Jonas Garcia
NPI 1770550931
$6,319.38
in general payments reported to CMS, 2019-2025
15 companies · $14.81 in 2025
The $14.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $1,516 · 2021: $1,418 · 2022: $1,705 · 2023: $545 · 2025: $14.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,645.74 | 2019-2023 | Gallant |
| Pfizer INC. | $499.23 | 2019-2022 | |
| Amgen INC. | $470.81 | 2019-2022 | |
| Amarin Pharma, INC. | $379.84 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $376.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.66 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $172.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $148.26 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $98.90 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $84.29 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.88 | 2021-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $41.29 | 2021 | |
| Boston Scientific Corporation | $20.13 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.81 | 2025 | Zilretta |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonas Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.